Immunotherapy or antiangiogenic therapy plus chemotherapy as <scp>first‐line</scp> treatment of patients with <scp>PD‐L1</scp>(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort
Cancer medicine